Precious Metal Catalysts: The Scavengers’ Guide
December 8, 2020
Platinum group (and other precious) metal catalysts are routinely used to synthesize APIs – but they are inherently expensive, so why not recover and recycle?
0 min read
November 2020
In the month’s issue, we examine what lessons from pandemic influenza can be applied to COVID-19 – featuring Russell Basser from Seqirus. We then move far beyond the pandemic to deep space – asking how biologic medicines can be made on-demand for astronauts on long-term space missions. In Profession, Ross T. Burn, CEO at CatSci walks us through the career experiences that have helped shape him, and in NextGen, we find out what can be done to reduce the global incidence of diabetes and its associated conditions. Brexit preparedness, precious metal catalysis, and post-pandemic pharma are all discussed in In My View. And finally, we sit down with Will Downie, CEO of Vectura Group, UK.
Down to Earth
November 28, 2020
Aiming for technologies that can make medicines in space or on Mars can also help us with problems closer to home, such as challenges with cold chain and getting medicines to remote locations
1 min read
Bringing Bioreactors to Space
November 27, 2020
Is it possible to design a bioreactor that can function in microgravity?
1 min read
Preparing for the Next Pandemic
November 19, 2020
Ever since the “bird flu” outbreaks of the mid-2000s, public health experts have been concerned about an influenza pandemic to rival the 1918 Spanish Flu. Now, blindsided by a less expected beast, can we transfer lessons on pandemic preparedness from flu to COVID-19? We caught up with Russell Basser, Head of R&D at flu vaccine manufacturer Seqirus to find out more about the past, present, and future of vaccine production – and how COVID-19 changes the outlook.
1 min read
Manufacture
Bioprocessing
Biopharma
Facilities & Equipment
Technology & Manufacturing
Development & Clinical
A Grueling Environment
November 18, 2020
1 min read
Informing Consent
November 16, 2020
Are seriously ill patients vulnerable to overestimating the benefits and underestimating the risks of gene editing studies?
1 min read
From Big Pharma to New Green Horizons: Lessons Learned with Ross Burn
November 16, 2020
With just a three-day crash course in business finance under his belt, analytical chemist Ross Burn co-founded CatSci in 2010. Here, he talks about surviving and thriving as a new company focused on process chemistry, alongside more recent moves into industry 4.0 and collaborations in the contract research space.
1 min read
Green Trials
November 14, 2020
Small changes in clinical trials could benefit the environment
1 min read
Getting the Job (Done)
November 12, 2020
Sitting Down With… Will Downie, CEO of Vectura Group, UK
1 min read
The Pandemic Diaries
November 10, 2020
We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis
1 min read
Diabetes: Finding a Panacea
November 10, 2020
What is pharma doing to reduce the global incidence of diabetes?
1 min read
Manufacture
Bioprocessing
Biopharma
Drug Discovery
Research News
Outsourcing
Technology & Manufacturing
Sponsored
Fighting Viruses with Enhanced ADCC
November 9, 2020
With evidence mounting for the importance of antibody-dependent cellular cytotoxicity in controlling viral infections, mAbs engineered to enhance the effect are primed for success
1 min read
Mass Spec Meets Machine learning
November 2, 2020
Can machine learning offer mass spectrometry a boost for drug discovery?
1 min read
Poisoning Pain
October 28, 2020
Investigating the pain-relieving properties of spider venom
1 min read
Brexit Trading Unknowns
October 15, 2020
Is your business prepared for Brexit? Here’s my advice.
0 min read
Mapping Out MAM
September 29, 2020
Amgen has brought the Multi-Attribute Method (MAM) into the mainstream, but what’s next for this analytical workflow – and for biopharmaceutical QC?
0 min read
Advanced Medicine In Brief
March 16, 2020
The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR-T picture… We examine what’s going on in advanced medicine
0 min read
